 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hormone/growth factor
|
PDB id
|
|
|
|
1pwa
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biochemical function
|
growth factor activity
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
43:629-640
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity.
|
|
N.J.Harmer,
L.Pellegrini,
D.Chirgadze,
J.Fernandez-Recio,
T.L.Blundell.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The 22 members of the FGF family have been implicated in cell proliferation,
differentiation, survival, and migration. They are required for both development
and maintenance of vertebrates, demonstrating an exquisite pattern of affinities
for both protein and proteoglycan receptors. FGF19, one of the most divergent
human FGFs, is unique in binding solely to one receptor, FGFR4. We have used
molecular replacement to solve the crystal structure of FGF19 at 1.3 A
resolution using five superimposed FGF structures as the search model. The
structure shows that two novel disulfide bonds found in FGF19, one of which
appears to be conserved among several of the other FGFs, stabilize extended
loops. The key heparin-binding loops of FGF19 have radically different
conformations and charge patterns, compared to other FGFs, correlating with the
unusually low affinity of FGF19 for heparin. A model for the complex of FGF19
with FGFR4 demonstrates that unique sequences in both FGF19 and FGFR4 are key to
the formation of the complex. The structure therefore offers a clear explanation
for the unusual affinity of FGF19 for FGFR4 alone.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
S.Riazuddin,
Z.M.Ahmed,
R.S.Hegde,
S.N.Khan,
I.Nasir,
U.Shaukat,
S.Riazuddin,
J.A.Butman,
A.J.Griffith,
T.B.Friedman,
and
B.Y.Choi
(2011).
Variable expressivity of FGF3 mutations associated with deafness and LAMM syndrome.
|
| |
BMC Med Genet, 12,
21.
|
 |
|
|
|
|
 |
M.Kuro-o
(2010).
Overview of the FGF23-Klotho axis.
|
| |
Pediatr Nephrol, 25,
583-590.
|
 |
|
|
|
|
 |
M.Kuro-o
(2010).
A potential link between phosphate and aging--lessons from Klotho-deficient mice.
|
| |
Mech Ageing Dev, 131,
270-275.
|
 |
|
|
|
|
 |
H.Kurosu,
and
M.Kuro-O
(2009).
Endocrine fibroblast growth factors as regulators of metabolic homeostasis.
|
| |
Biofactors, 35,
52-60.
|
 |
|
|
|
|
 |
M.Rydén
(2009).
Fibroblast growth factor 21: an overview from a clinical perspective.
|
| |
Cell Mol Life Sci, 66,
2067-2073.
|
 |
|
|
|
|
 |
R.Micanovic,
D.W.Raches,
J.D.Dunbar,
D.A.Driver,
H.A.Bina,
C.D.Dickinson,
and
A.Kharitonenkov
(2009).
Different roles of N- and C- termini in the functional activity of FGF21.
|
| |
J Cell Physiol, 219,
227-234.
|
 |
|
|
|
|
 |
X.Wu,
H.Ge,
B.Lemon,
J.Weiszmann,
J.Gupte,
N.Hawkins,
X.Li,
J.Tang,
R.Lindberg,
and
Y.Li
(2009).
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
|
| |
Proc Natl Acad Sci U S A, 106,
14379-14384.
|
 |
|
|
|
|
 |
B.A.Kwiatkowski,
I.Kirillova,
R.E.Richard,
D.Israeli,
and
Z.Yablonka-Reuveni
(2008).
FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.
|
| |
J Cell Physiol, 215,
803-817.
|
 |
|
|
|
|
 |
H.Kurosu,
and
M.Kuro-o
(2008).
The Klotho gene family and the endocrine fibroblast growth factors.
|
| |
Curr Opin Nephrol Hypertens, 17,
368-372.
|
 |
|
|
|
|
 |
L.R.Desnoyers,
R.Pai,
R.E.Ferrando,
K.Hötzel,
T.Le,
J.Ross,
R.Carano,
A.D'Souza,
J.Qing,
I.Mohtashemi,
A.Ashkenazi,
and
D.M.French
(2008).
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
|
| |
Oncogene, 27,
85-97.
|
 |
|
|
|
|
 |
M.Kuro-o
(2008).
Endocrine FGFs and Klothos: emerging concepts.
|
| |
Trends Endocrinol Metab, 19,
239-245.
|
 |
|
|
|
|
 |
U.Borello,
I.Cobos,
J.E.Long,
C.Murre,
and
J.L.Rubenstein
(2008).
FGF15 promotes neurogenesis and opposes FGF8 function during neocortical development.
|
| |
Neural Develop, 3,
17.
|
 |
|
|
|
|
 |
X.Wu,
B.Lemon,
X.Li,
J.Gupte,
J.Weiszmann,
J.Stevens,
N.Hawkins,
W.Shen,
R.Lindberg,
J.L.Chen,
H.Tian,
and
Y.Li
(2008).
C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors.
|
| |
J Biol Chem, 283,
33304-33309.
|
 |
|
|
|
|
 |
Y.Yamazaki,
T.Tamada,
N.Kasai,
I.Urakawa,
Y.Aono,
H.Hasegawa,
T.Fujita,
R.Kuroki,
T.Yamashita,
S.Fukumoto,
and
T.Shimada
(2008).
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23.
|
| |
J Bone Miner Res, 23,
1509-1518.
|
 |
|
|
|
|
 |
B.C.Lin,
M.Wang,
C.Blackmore,
and
L.R.Desnoyers
(2007).
Liver-specific activities of FGF19 require Klotho beta.
|
| |
J Biol Chem, 282,
27277-27284.
|
 |
|
|
|
|
 |
H.Kurosu,
M.Choi,
Y.Ogawa,
A.S.Dickson,
R.Goetz,
A.V.Eliseenkova,
M.Mohammadi,
K.P.Rosenblatt,
S.A.Kliewer,
and
M.Kuro-o
(2007).
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.
|
| |
J Biol Chem, 282,
26687-26695.
|
 |
|
|
|
|
 |
R.Goetz,
A.Beenken,
O.A.Ibrahimi,
J.Kalinina,
S.K.Olsen,
A.V.Eliseenkova,
C.Xu,
T.A.Neubert,
F.Zhang,
R.J.Linhardt,
X.Yu,
K.E.White,
T.Inagaki,
S.A.Kliewer,
M.Yamamoto,
H.Kurosu,
Y.Ogawa,
M.Kuro-o,
B.Lanske,
M.S.Razzaque,
and
M.Mohammadi
(2007).
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members.
|
| |
Mol Cell Biol, 27,
3417-3428.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
X.Wu,
H.Ge,
J.Gupte,
J.Weiszmann,
G.Shimamoto,
J.Stevens,
N.Hawkins,
B.Lemon,
W.Shen,
J.Xu,
M.M.Veniant,
Y.S.Li,
R.Lindberg,
J.L.Chen,
H.Tian,
and
Y.Li
(2007).
Co-receptor requirements for fibroblast growth factor-19 signaling.
|
| |
J Biol Chem, 282,
29069-29072.
|
 |
|
|
|
|
 |
A.Canales-Mayordomo,
R.Fayos,
J.Angulo,
R.Ojeda,
M.Martín-Pastor,
P.M.Nieto,
M.Martín-Lomas,
R.Lozano,
G.Giménez-Gallego,
and
J.Jiménez-Barbero
(2006).
Backbone dynamics of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation methods.
|
| |
J Biomol NMR, 35,
225-239.
|
 |
|
|
|
|
 |
M.L.Robinson
(2006).
An essential role for FGF receptor signaling in lens development.
|
| |
Semin Cell Dev Biol, 17,
726-740.
|
 |
|
|
|
|
 |
Y.Luo,
S.Ye,
M.Kan,
and
W.L.McKeehan
(2006).
Structural specificity in a FGF7-affinity purified heparin octasaccharide required for formation of a complex with FGF7 and FGFR2IIIb.
|
| |
J Cell Biochem, 97,
1241-1258.
|
 |
|
|
|
|
 |
C.Chen,
S.Patel,
S.Corisdeo,
X.Liu,
H.Micolochick,
J.Xue,
Q.Yang,
Y.Lei,
B.Wang,
and
D.Soltis
(2005).
Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4).
|
| |
Hybridoma (Larchmt), 24,
152-159.
|
 |
|
|
|
|
 |
C.Yu,
F.Wang,
C.Jin,
X.Huang,
and
W.L.McKeehan
(2005).
Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids.
|
| |
J Biol Chem, 280,
17707-17714.
|
 |
|
|
|
|
 |
H.Kurose,
M.Okamoto,
M.Shimizu,
T.Bito,
C.Marcelle,
S.Noji,
and
H.Ohuchi
(2005).
FGF19-FGFR4 signaling elaborates lens induction with the FGF8-L-Maf cascade in the chick embryo.
|
| |
Dev Growth Differ, 47,
213-223.
|
 |
|
|
|
|
 |
M.Mohammadi,
S.K.Olsen,
and
O.A.Ibrahimi
(2005).
Structural basis for fibroblast growth factor receptor activation.
|
| |
Cytokine Growth Factor Rev, 16,
107-137.
|
 |
|
|
|
|
 |
O.A.Ibrahimi,
B.K.Yeh,
A.V.Eliseenkova,
F.Zhang,
S.K.Olsen,
M.Igarashi,
S.A.Aaronson,
R.J.Linhardt,
and
M.Mohammadi
(2005).
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization.
|
| |
Mol Cell Biol, 25,
671-684.
|
 |
|
|
|
|
 |
T.Inagaki,
M.Choi,
A.Moschetta,
L.Peng,
C.L.Cummins,
J.G.McDonald,
G.Luo,
S.A.Jones,
B.Goodwin,
J.A.Richardson,
R.D.Gerard,
J.J.Repa,
D.J.Mangelsdorf,
and
S.A.Kliewer
(2005).
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.
|
| |
Cell Metab, 2,
217-225.
|
 |
|
|
|
|
 |
T.Yamashita
(2005).
Structural and biochemical properties of fibroblast growth factor 23.
|
| |
Ther Apher Dial, 9,
313-318.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|